Waveline-001: Updated Results from a Phase 1 Dose Escalation and Cohort Expansion Study of Zilovertamab Vedotin (MK-2140) in Non-Hodgkin Lymphoma

Spurgeon, Stephen E.; Mei, Matthew; Barr, Paul M.; Barrientos, Jacqueline C.; Vos, Sven de; Furman, Richard R.; Patel, Krish; Thompson, Philip A.; Choi, Michael Y.; Kallam, Avyakta; Wang, Sirou; Ogbu, Uzor C.; Nahar, Akash; Wang, Michael L.

doi:10.1182/blood-2022-163509

Cited by 9 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The WAVELINE-001 study investigated the role of zilovertamab vedotin (MK-2140), which is an antibody-drug conjugate comprising a humanized IgG1 monoclonal antibody and the antimicrotubule cytotoxic agent monomethyl auristatin E (MMAE), in patients with relapsed/refractory NHLs. Recently reported results included seven patients with RT, four of whom responded, with a median duration of response of 2.8 months [71].…”

Section: Ror1-targeting Antibody-drug Conjugatementioning

confidence: 99%

Update on management of diffuse large B-cell lymphoma Richter's transformation

Sośnia,

Puła

2024

Acta Haematol Pol.

View full text Add to dashboard Cite

Richter's transformation (RT) is defined as the development of an aggressive lymphoma in 2-10% of patients with chronic lymphocytic leukemia (CLL). Despite significant advances in the last decade, there is currently no established standard of care for RT, making its management a significant challenge. Questions regarding patients' treatment management in the era of novel agents and targeted therapies have yet to be answered. Nevertheless, several retrospective studies and clinical trials have emphasized the use of novel targeted agents to address this problem. In this review, we provide a summary of potential therapeutic options for RT.

show abstract

Section: Ror1-targeting Antibody-drug Conjugatementioning

confidence: 99%

Update on management of diffuse large B-cell lymphoma Richter's transformation

Sośnia,

Puła

2024

Acta Haematol Pol.

View full text Add to dashboard Cite

show abstract

“…Given advancements in drug development, there are various other trials currently underway for the treatment of RT. The WAVELINE-001 study is a phase 1 trial of antibody drug conjugate, zilovertamab vedotin [ 72 ]. This drug targets receptor tyrosine kinase-like orphan receptor 1 (ROR1), a cell surface protein expressed on de-differentiated cancer cells, but absent in mature tissues.…”

Section: Other Novel-targeted Agents and Upcoming Trialsmentioning

confidence: 99%

“…ORR was 57% in the RT cohort with 3 patients achieving CR and 1 patient achieving PR. Median PFS and OS were 4.7 and 24 months respectively [ 72 ].…”

Section: Other Novel-targeted Agents and Upcoming Trialsmentioning

confidence: 99%

Treatment of Richter’s Transformation with Novel Therapies

Bajwa,

Habib,

Kittai

2024

Curr Hematol Malig Rep

View full text Add to dashboard Cite

Purpose of Review This review presents recently published clinical trial data and ongoing investigations regarding the treatment of Richter’s transformation (RT). Recent Findings Recently, numerous approaches have been investigated for the treatment of RT including: traditional chemoimmunotherapy regimens combined with targeted agents such as BTKi and BCL2i; immunotherapy combined with targeted agents; non-covalent BTKis; bispecific T cell engagers; and CART therapy. In addition, various novel targeted agents are currently being studied for the treatment of RT in phase 1 and 2 clinical trials. Summary Standard of care treatment with chemoimmunotherapy for RT has limited efficacy in achieving durable remissions. Here, we review recent data on the use of combination treatments and targeted agents in RT. Although some progress has been made in the investigation to optimize treatment of RT, further study is needed to evaluate long term outcomes of recently published trials and test efficacy of upcoming novel agents.

show abstract

“…Neutropenia and peripheral neuropathy were the most significant adverse events recorded. 138 Bispecific antibodies recruit T cells to tumour cells and show great promise in B-cell lymphomas. [139][140][141] Glofitamab is under investigation specifically in MCL, using standardised step-up dosing and obinutuzumab priming.…”

Section: Management Options For Patients Who Are Failed By a Covalent...mentioning

confidence: 99%

“…Zilovertamab vedotin is an immunoconjugate targeting ROR1, carrying the toxin monomethyl auristatin E. Of 17 patients enrolled following cBTKi, there were nine responses with a median DOR of 10.0 (0–20.3) months. Neutropenia and peripheral neuropathy were the most significant adverse events recorded 138 …”

Section: Recommendationsmentioning

confidence: 99%

Diagnosis and management of mantle cell lymphoma: A British Society for Haematology Guideline

Eyre,

Bishton,

McCulloch

et al. 2023

Br J Haematol

View full text Add to dashboard Cite

The objective of this guideline is to provide healthcare professionals with clear guidance on the diagnosis and management of patients with mantle cell lymphoma. M ETHODOLOGYThis Guideline was compiled according to the BSH process at https:// b-s-h. org. uk/ media/ 16732/ bsh-guida nce-devel opmen t-proce ss-dec-5-18. pdf and represents best practice in both teaching and district hospitals in the United Kingdom. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) nomenclature was used to evaluate the levels of evidence and to assess the strength of recommendations. The GRADE criteria can be found at http:// www. grade worki nggro up. org. Literature review detailsRecommendations included a systematic review of published English language literature from publication of previous British Society for Haematology (BSH) Management of Mantle Cell lymphoma Guidelines 2018 up to 02/2023. The search was limited to English language publications and conference abstracts. Titles/abstracts obtained were curated and manually reviewed by the writing group who conducted additional searches, using sub-section heading terms. In addition, there are some further pertinent references and a consensus of expert opinion where no published data are available. PubMed, MEDLINE, Embase, Cochrane databases and Web of Science were searched using the preliminary search terms: MCL OR Mantle Cell lymphoma OR aggressive Mantle Cell lymphoma OR indolent Mantle Cell lymphoma. Systematic reviews, meta-analysis including guidelines from other countries, prospective clinical trials,

show abstract

Waveline-001: Updated Results from a Phase 1 Dose Escalation and Cohort Expansion Study of Zilovertamab Vedotin (MK-2140) in Non-Hodgkin Lymphoma

Cited by 9 publications

References 0 publications

Update on management of diffuse large B-cell lymphoma Richter's transformation

Update on management of diffuse large B-cell lymphoma Richter's transformation

Treatment of Richter’s Transformation with Novel Therapies

Diagnosis and management of mantle cell lymphoma: A British Society for Haematology Guideline

Contact Info

Product

Resources

About